Pfizer enCompass Co-Pay Assistance Program
Pfizer
The Pfizer enCompass Co-Pay Assistance Program for ABRILADA helps eligible privately insured patients reduce their out-of-pocket costs for ABRILADA treatment to as little as $0. The program provides a maximum annual benefit ranging from $4,000 to $14,000 for co-pays or coinsurances. Patients are ineligible if they have state or federally funded insurance, are cash-paying, or are prescribed ABRILADA for adolescent HS, pediatric uveitis, or pediatric ulcerative colitis.
- Covers
- financial assistance
- Enrollment cycle
- annual
Apply
Application goes directly to Pfizer. RxCopays does not receive compensation.
Go to application →Status source
Enrollment required.
Rare-disease support beyond financial help
This grant covers 12 rare conditions. For specialists, clinical trials, and patient communities, our sister site UniteRare.org has in-depth pages: